SKP2 and breast cancer: For luminal A type BC patients, FBXO1 (HR = 1.46 95%CI: 1.02–2.08, P=0.0358), SKP2 (HR = 1.80 95%CI: 1.25-2.57, P=0.0012), and FBXO5 (HR = 1.92 95%CI: 1.33–2.76, P=0.0004) were correlated to worse survival (Figure 2A–C).